Suppr超能文献

逍遥散治疗重度抑郁症的分子机制:大鼠弓状核DNA甲基化与RNA测序的综合分析

The molecular mechanism of Xiaoyaosan in treating major depressive disorder: Integrated analysis of DNA methylation and RNA sequencing of the arcuate nucleus in rats.

作者信息

Wang Rongyanqi, Zou Tan, Wang Yidi, Liu Yueyun, Mo Xiaowei, Chen Yueyue, Li Xiaojuan, Chen Jiaxu

机构信息

School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, PR China.

Guangzhou Key Laboratory of Formula-Pattern of Traditional Chinese Medicine, Formula-Pattern Research Center, School of Traditional Chinese Medicine, Jinan University, Guangzhou, 510632, PR China.

出版信息

J Ethnopharmacol. 2025 Jan 31;340:119234. doi: 10.1016/j.jep.2024.119234. Epub 2024 Dec 14.

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE

Xiaoyaosan, a classic Chinese herbal formula, exhibits promising antidepressant effects. However, its specific antidepressant mechanisms remain incompletely understood. Previous studies have highlighted the significant role of DNA methylation in the pathogenesis of major depressive disorder (MDD). Yet, whether the effects of Xiaoyaosan are linked to DNA methylation and its regulation remains unclear.

AIM OF THE STUDY

This study aims to explore and verify the molecular mechanism of Xiaoyaosan in treating MDD via integrated analysis of DNA methylation and RNA sequencing.

MATERIALS AND METHODS

In this study, a chronic unpredictable mild stress (CUMS) model was established to induce MDD in rats, which were subsequently orally treated with Xiaoyaosan, with fluoxetine as a positive control. Antidepressant effects were assessed by the open field test, sucrose preference test, and forced swimming test. Whole-genome bisulfite sequencing (WGBS) and bulk RNA sequencing were performed in the arcuate nucleus of hypothalamus to assess methylation changes and identify differentially expressed genes. Bioinformatics analyses were conducted to explore methylation alterations, RNA sequencing profiles, and their shared epigenetic as well as gene expression changes, to identify candidate genes. Finally, RT-PCR was used to validate the key differential genes.

RESULTS

Xiaoyaosan effectively reversed depressive-like behaviors. Further, Xiaoyaosan treatment involved multiple epigenetic modifications. The results of differentially methylated genes showed that there were 1353 overlapped genes between M-vs-C-hypo gene and X-vs-M-hyper gene, 5326 overlapped genes between M-vs-C-hyper gene and X-vs-M-hypo gene. GO and KEGG enrichment analyses indicated these intersecting genes were involved in biological regulation, transcription factors, appetite and endocrine control systems, etc. The analysis of differentially expressed genes from RNA sequencing revealed that there were 25 overlapping genes between the M vs C hypomethylated group and the X vs M hypermethylated group, while 81 overlapping genes were identified between the M vs C hypermethylated group and the X vs M hypomethylated group. Those differential genes regulated by methylation enriched in processes related to brain and neuronal growth, neuropeptide and hormone activation, as well as biological processes and molecular functions associated with protein translation, synthesis, transport, and localization. The integrated analysis of DNA methylation and RNA sequencing screened 14 potentially differential genes, which were associated with appetite regulation, energy metabolism, and neuroreceptor ligands. PCR verification found that Lmx1b, Abcc5, Gpc3 and Cfb showed statistical differences.

CONCLUSIONS

The antidepressant mechanism of Xiaoyaosan involves the biological regulation in the arcuate nucleus of hypothalamus, including transcription factors, neurotransmitter regulation, neural development, appetite regulation peptides, and endocrine control systems. The methylation level and regulation at the gene locus of Lmx1b, Abcc5, Gpc3, and Cfb may play a key role in the treatment of Xiaoyaosan. These findings provide new insights into the therapeutic mechanisms of Xiaoyaosan.

摘要

民族药理学相关性

逍遥散是一种经典的中药方剂,具有显著的抗抑郁作用。然而,其具体的抗抑郁机制仍未完全明确。此前的研究强调了DNA甲基化在重度抑郁症(MDD)发病机制中的重要作用。然而,逍遥散的作用是否与DNA甲基化及其调控相关仍不清楚。

研究目的

本研究旨在通过对DNA甲基化和RNA测序的综合分析,探索并验证逍遥散治疗MDD的分子机制。

材料与方法

在本研究中,建立慢性不可预测温和应激(CUMS)模型诱导大鼠患MDD,随后对其进行逍遥散灌胃治疗,以氟西汀作为阳性对照。通过旷场试验、蔗糖偏好试验和强迫游泳试验评估抗抑郁效果。在下丘脑弓状核进行全基因组亚硫酸氢盐测序(WGBS)和大量RNA测序,以评估甲基化变化并鉴定差异表达基因。进行生物信息学分析以探索甲基化改变、RNA测序图谱及其共同的表观遗传以及基因表达变化,从而鉴定候选基因。最后,使用RT-PCR验证关键差异基因。

结果

逍遥散有效逆转了抑郁样行为。此外,逍遥散治疗涉及多种表观遗传修饰。差异甲基化基因的结果显示,M-vs-C低甲基化基因与X-vs-M高甲基化基因之间有1353个重叠基因,M-vs-C高甲基化基因与X-vs-M低甲基化基因之间有5326个重叠基因。基因本体(GO)和京都基因与基因组百科全书(KEGG)富集分析表明,这些交叉基因参与生物调节、转录因子、食欲和内分泌控制系统等。RNA测序差异表达基因分析显示,M与C低甲基化组和X与M高甲基化组之间有25个重叠基因,而M与C高甲基化组和X与M低甲基化组之间鉴定出81个重叠基因。这些受甲基化调控的差异基因富集于与脑和神经元生长、神经肽和激素激活以及与蛋白质翻译、合成、运输和定位相关的生物过程和分子功能。DNA甲基化和RNA测序的综合分析筛选出14个潜在差异基因,这些基因与食欲调节、能量代谢和神经受体配体相关。PCR验证发现Lmx1b、Abcc5、Gpc3和Cfb存在统计学差异。

结论

逍遥散的抗抑郁机制涉及下丘脑弓状核的生物调节,包括转录因子、神经递质调节、神经发育、食欲调节肽和内分泌控制系统。Lmx1b、Abcc5、Gpc3和Cfb基因位点的甲基化水平及其调控可能在逍遥散治疗中起关键作用。这些发现为逍遥散的治疗机制提供了新的见解。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验